This article is more than 5 years old. Information may no longer be current.
Survey suggests treatment trends largely unaffected by CATT 1-year results
Click Here to Manage Email Alerts
BOSTON — A survey presented here illustrated retina specialists' preferences regarding the use of anti-VEGF therapy for various diseases.
According to a preferences and trends survey completed by members of the American Society of Retina Specialists, 73.24% of surgeons have continued the same treatment for wet age-related macular degeneration despite publication of 1-year CATT results. A little more than 7% switched from Lucentis (ranibizumab, Genentech) to Avastin (bevacizumab, Genentech).
For patients who receive anti-VEGF therapy bilaterally, 53.3% of surgeons inject the two eyes during the same office visit, while 44.25% inject one eye per visit.
For initial treatment of perfused branch retinal vein occlusion, macular edema and visual acuity of 20/60, 66.23% of physicians prefer bevacizumab.
For the initial treatment of diffuse diabetic macular edema with a visual acuity of 20/60, 43.87% of surgeons prefer intravitreal bevacizumab followed by laser, and another 24.94% prefer bevacizumab alone.
While a majority of survey contributors said they do not think the federal government should sponsor a trial between ranibizumab and bevacizumab for the treatment of central retinal vein occlusion and branch retinal vein occlusion, a majority supported such a trial for diabetic macular edema.